Search Results

June 3, 2024

DARZALEX® (daratumumab)-based regimens significantly improve clinical outcomes in both transplant-eligible and -ineligible patients who are newly diagnosed with multiple myeloma

88 percent of transplant-eligible patients achieved a complete response or better, and 47 percent of patients sustained MRD-negativity for longer than one year with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based induction, consolidation and maintenance regimens in the Phase 3 PERSEUS study 7.5 years median overall survival achieved with DARZALEX®-based regimen in Phase 3 MAIA final analysis is the longest reported in patients ineligible for transplant

Innovative Medicine

June 3, 2024

Late-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib show clinically meaningful antitumor response and improved safety profile in patients with EGFR-mutated non-small cell lung cancer

Significantly lower infusion-related reactions seen with subcutaneous amivantamab compared with intravenous administration in new Phase 2 data

Innovative Medicine

June 3, 2024

TECVAYLI® (teclistamab-cqyv) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma

New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched to biweekly dosing1 Separate analyses from the MajesTEC-1 and OPTec studies are the first to underscore the opportunity for outpatient administration of TECVAYLI®

Innovative Medicine

May 31, 2024

First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration

New formulation showed non-inferiority to intravenous administration in fourth positive Phase 3 study in RYBREVANT® clinical program Longer overall survival, progression-free survival and duration of response shown with subcutaneous amivantamab; featured in Best of ASCO 2024 RYBREVANT® marketing application submitted to European Medicines Agency based on PALOMA-3 study

Innovative Medicine

May 31, 2024

RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer progression-free survival versus osimertinib in first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer

Investigational chemotherapy-free regimen of RYBREVANT® plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease Landmark Phase 3 MARIPOSA data featured in an oral presentation at ASCO

Innovative Medicine

May 23, 2024

Johnson & Johnson advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA

PALOMA-3 presentation of subcutaneous amivantamab and lazertinib selected to showcase cutting-edge approaches in lung cancer during prestigious “Best of ASCO” program New data showcase first- and -best-in-class, complementary multiple myeloma therapies, including DARZALEX® (daratumumab), CARVYKTI® (ciltacabtagene autoleucel; cilta-cel), TECVAYLI® (teclistamab-cqyv) and TALVEY® (talquetamab-tgvs)

Innovative Medicine

May 20, 2024

TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission

Innovative Medicine

May 16, 2024

Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment

Acquisition advances Johnson & Johnson’s leading Dermatology portfolio with opportunity to address significant unmet need in atopic dermatitis (AD) Includes bispecific antibodies targeting proven disease pathways and offers the potential to provide best-in-disease therapeutics for people with moderate to severe AD and asthma These pipeline additions demonstrate the Company’s strategic approach to build a portfolio of differentiated and complementary bispecifics to address multiple disease-driving pathways

Innovative Medicine

May 6, 2024

TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non–muscle-invasive bladder cancer, respectively

Updated results reinforce the potential of TAR-210 to transform treatment of non–muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterations

Innovative Medicine

May 3, 2024

Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery

Study highlights opportunity for treatment intensification in this population since approximately 50% of patients with high-risk localized prostate cancer (HRLPC) experience disease recurrence within two years of surgery

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine